SUBSCRIBE
SUBSCRIBE

Phase I

Drug Development
Biopharma Industry News for March 27: Update on the Novel Coronavirus
A summary of daily biopharma industry news. Please check out stories that are trending on March 27, 2020.
March 27, 2020
 · 
3 min read
 · 
BioSpace Editorial Staff
Drug Development
Biopharma Industry News for March 26: Update on the Novel Coronavirus
A summary of daily biopharma industry news. Please check out stories that are trending on March 26, 2020.
March 26, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Drug Development
Biopharma Industry News for March 25: Update on the Novel Coronavirus
A summary of daily biopharma industry news. Please check out stories that are trending on March 25, 2020.
March 25, 2020
 · 
7 min read
 · 
BioSpace Editorial Staff
Drug Development
Biopharma Industry News for March 24: Update on the Novel Coronavirus
A summary of daily biopharma industry news. Please check out stories that are trending on March 24, 2020.
March 24, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Drug Development
Eli Lilly Among Companies Pausing Some Clinical Trials Due to COVID-19 Pandemic
This morning, the Indianapolis-based company said it will delay most new study starts and pause enrollment in most ongoing studies in light of the COVID-19 pandemic.
March 23, 2020
 · 
3 min read
 · 
Alex Keown
Drug Development
Biopharma Industry News for March 23: Update on the Novel Coronavirus
A summary of daily biopharma industry news. Please check out stories that are trending on March 23, 2020.
March 23, 2020
 · 
6 min read
 · 
BioSpace Editorial Staff
BioCapital
Clinical Catch-Up: March 16-20
Here’s a look at some of last week’s clinical trial news.
March 20, 2020
 · 
7 min read
 · 
Mark Terry
Drug Development
Biopharma Industry News for March 20: Update on the Novel Coronavirus
A summary of daily Biopharma industry news. Please check out stories that are trending on March 20, 2020.
March 20, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Drug Development
Biopharma Industry News for March 19: Update on the Novel Coronavirus
A summary of daily Biopharma industry news. Please check out stories that are trending on March 19, 2020.
March 19, 2020
 · 
3 min read
 · 
BioSpace Editorial Staff
Drug Development
Findings Reveal Lack of Participants in Critical Research is Caused by Fear
Researchers found fear of testing new treatments and possible side effects were common denominators among patients.
March 17, 2020
 · 
2 min read
 · 
Michelle Brugioni
Load More
PRESS RELEASES
Press Releases
Alessa Therapeutics Announces FDA Fast Track Designation for Enolen, A First-Of-Its-Kind Treatment for Localized Prostate Cancer
January 9, 2026
 · 
3 min read
Press Releases
Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis
January 9, 2026
 · 
9 min read
Press Releases
Ollin Biosciences Announces Positive Topline Data with Superior Outcomes from a Randomized Head-to-Head Study of OLN324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular Degeneration
January 9, 2026
 · 
6 min read
Press Releases
MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease
January 9, 2026
 · 
7 min read
Press Releases
Aspen Neuroscience Completes Phase 1/2a ASPIRO Trial Cohort Three Dosing and State-of-the-Art Manufacturing Expansion, Paving the Way for Developing Transformative Therapies for Patients
January 9, 2026
 · 
4 min read
Press Releases
BioVaxys Announces Phase 1 Clinical Study Results Advancing DPX(TM)-Formulated Products in Patients with Non-Muscle Invasive Bladder Cancer
January 8, 2026
 · 
9 min read
Press Releases
Epirium Bio Announces Follow-on Phase 1 Results in Older Adult Participants for MF-300, a First-In-Class, Oral 15-PGDH Enzyme Inhibitor, for the Treatment of Sarcopenia
January 8, 2026
 · 
4 min read
Press Releases
VectorY Therapeutics Receives FDA Fast Track Designation for VTx-002, a First-in-Class Vectorized Antibody Targeting Underlying Disease Biology in ALS
January 8, 2026
 · 
3 min read
Press Releases
SpliceBio Initiates Dose-Expansion Portion of Phase 1/2 ASTRA Clinical Trial for SB-007, a Dual-AAV Gene Therapy for Stargardt Disease
January 8, 2026
 · 
6 min read
Press Releases
Virometix AG Announces Positive Data from Phase 1 Trial of V-212, a Fully Synthetic, Serotype-Independent Vaccine Development Candidate for the Prevention of Pneumococcal Disease
January 8, 2026
 · 
4 min read
Press Releases
Whitehawk Therapeutics Advances to Clinical Stage with IND Clearance for HWK-007 and Announces IND Submission for HWK-016
January 8, 2026
 · 
6 min read
Press Releases
ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook
January 8, 2026
 · 
11 min read
Press Releases
Revolution Medicines Announces FDA Breakthrough Therapy Designation for Zoldonrasib
January 8, 2026
 · 
6 min read
Press Releases
Atsena Completes Dosing in Part B of the Phase I/II/III LIGHTHOUSE Trial Evaluating ATSN-201 to Treat X-linked Retinoschisis and Announces Plans for Initiation of Pivotal Part C Cohort
January 8, 2026
 · 
6 min read
Press Releases
Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy
January 8, 2026
 · 
11 min read
Press Releases
Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen
January 8, 2026
 · 
4 min read
Press Releases
Antag Therapeutics demonstrates compelling potential of its novel GIPR antagonist for obesity, reporting excellent tolerability in Phase 1 and enhanced weight loss in amylin combination study
January 8, 2026
 · 
5 min read
Press Releases
Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria
January 8, 2026
 · 
10 min read
Press Releases
Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases
January 8, 2026
 · 
11 min read
Press Releases
Agomab Announces Positive Phase 1 Interim Results with AGMB-447 in Healthy Participants and Initiation of Idiopathic Pulmonary Fibrosis Cohort
January 8, 2026
 · 
4 min read
Load More